Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13380382 | 0.87 | SIGMAR1 (0.44) | SIGMAR1SLC6A4SLC6A2GNAI3GNAO1 | |
| SCHEMBL6529488 | 0.85 | GNAO1 (0.42) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL20363956 | 0.84 | GNAO1 (0.44) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL13636463 | 0.84 | GNAO1 (0.44) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL4308599 | 0.84 | GNAO1 (0.44) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL27736675 | 0.84 | GNAO1 (0.44) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL20363958 | 0.84 | GNAO1 (0.44) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL19630484 | 0.83 | KDM4E (0.38) | MEN1KMT2AGAA | |
| SCHEMBL11573468 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL4377618 | 0.82 | GNAO1 (0.47) | SIGMAR1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| US-5441959-A | Hypotensive agents; treating congestive heart failure and glaucoma,inhibiting restenosis | MERCK & CO., INC. (US) | 1995-08-15 | — | — | US | claimed |
| EP-0094498-A2 | Antiatherosclerotic 1-piperazine derivatives | AMERICAN CYANAMID COMPANY (US) | 1983-11-23 | — | — | EP | claimed |
| CN-118834313-A | Zwitterionic polymer, ion exchange membrane, and preparation methods and applications thereof | 佛山绿动氢能科技有限公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-07-04 | — | — | US | disclosed |
| CN-117487047-A | Phosphonic acid functionalized polymer, multifunctional styrene polymer and application thereof | 国家电投集团氢能科技发展有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117362485-A | Hydroxymethyl functionalized vinyl polymers, multifunctional polymers and uses thereof | 国家电投集团氢能科技发展有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| EP-3135672-B9 | COMPOSITIONS AND METHODS FOR TREATING ALCOHOL USE DISORDERS, PAIN AND OTHER DISEASES | VM DISCOVERY INC (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-0885213-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0885213-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997025323-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
| US-5441959-A | Hypotensive agents; treating congestive heart failure and glaucoma,inhibiting restenosis | MERCK & CO., INC. (US) | 1995-08-15 | — | — | US | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
| US-4439606-A | ANTICHOLESTEROL, ANTILIPEMIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1984-03-27 | — | — | US | disclosed |
| EP-0094498-A2 | Antiatherosclerotic 1-piperazine derivatives | AMERICAN CYANAMID COMPANY (US) | 1983-11-23 | — | — | EP | disclosed |
| EP-0049683-A2 | Imidazo-rifamycines, process for their preparation, pharmaceutical preparations containing them and their use | CIBA-GEIGY AG (CH) | 1982-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | PNLIP, LIPA, PHOSPHO1 | SIGMAR1 2805/4885SLC6A4 3430/4885SLC6A2 2968/4885 |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | SIGMAR1 3941/4885SLC6A4 3354/4885SLC6A2 3586/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | SIGMAR1 2011/4885SLC6A4 1909/4885SLC6A2 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.